ReviewMolecular biology reports2026
Natural compounds: a promising therapeutic option for managing colistin-resistant bacteria and improving colistin activity.
Review in Molecular biology reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Emerging hypervirulent and extensively drug-resistant Klebsiella pneumoniae with potent biofilm formation as a new clinical challenge.Molecular biology reports · 2026Article
- Trends of antimicrobial resistance in bloodstream infections at a large traditional Chinese medicine hospital in China: a 10-year surveillance study (2015-2024).BMC infectious diseases · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The rapid spread of multidrug-resistant bacteria, especially those resistant to the last-line treatment, colistin, has created an urgent demand for alternative or adjunctive therapies. In this context, natural compounds have attracted attention for their intrinsic antibacterial properties and potential to synergize with existing antibiotics. Recent studies have highlighted several natural compounds, including quercetin, cinnamaldehyde, thymol, eugenol, carvacrol, resveratrol, curcumin, farnesol, and apigenin, with notable inhibitory effects against colistin-resistant bacteria. Beyond their independent antibacterial activity, these compounds have shown synergistic interactions with colistin. Their combination reduced the minimum inhibitory concentration (MIC) of colistin and, in some cases, even restored bacterial susceptibility to it. These compounds exert their effects through mechanisms such as interacting with the MCR-1 protein to inhibit its function, downregulating virulence gene expression, and suppressing efflux pumps. Natural compounds can inhibit biofilm formation and disrupt mature biofilms. By compromising membrane integrity, they promote leakage of intracellular contents and also enhance antibiotic penetration. Promising results from in vivo studies using animal models indicate the potential of these compounds for clinical application. Nonetheless, further research is essential to fully validate their safety and effectiveness before clinical implementation. This review aims to provide a comprehensive overview of the antibacterial properties and mechanisms of action of natural compounds against colistin-resistant bacteria, with a special focus on their potential to restore colistin efficacy. It aims to guide future research and support the development of clinically applicable treatment strategies.
Indexed as
Identifiers
41706234What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.